A Cohort IND Expanded Access Program (EAP) for Tebentafusp for Treatment of HLA-A*02:01 Positive Patients With Metastatic Uveal Melanoma
Latest Information Update: 25 Jan 2022
At a glance
- Drugs Tebentafusp (Primary)
- Indications Uveal melanoma
- Focus Expanded access; Therapeutic Use
- Sponsors Immunocore
- 21 Jul 2021 New trial record